Canopy Growth’s (NYSE:CGC,TSX:WEED) board has dismissed Bruce Linton, co-founder and co-CEO of the Canadian cannabis producer, as its leading executive.

On Wednesday (July 3) the Canadian cannabis producer confirmed Linton would be departing the company effective immediately.

Fellow Canopy Growth co-CEO Mark Zekulin will become the sole CEO for the firm. However, he will participate in the search for new leadership.

In an interview with Squawk Box, Linton confirmed he did not step down from the firm but instead was terminated.

The now departing executive said once Canopy Growth closed on the second investment injection worth C$5 billion from Constellation Brands (NYSE:STZ) last August, a condition was set for the board to be reconfigured. The New York-based alcohol company currently holds a 38 percent stake in Canopy Growth.

“I think the board had decided they wanted a different chair and a different co-CEO,” Linton said during a televised interview. “So I’m out effective immediately and there’s a search to replace the transitioning co-CEO.”

Despite termination, Linton shows support for Canopy Growth

Under Linton’s tenure, Canopy grew from the first publicly traded marijuana company in Canada to obtain a New York Stock Exchange listing and having a current market valuation of C$18.45 billion.

In a statement, Linton said that, while his turn at the company was over, he was confident in the team replacing him.

“I personally remain committed to a successful transition over the coming year as we begin a process to identify new leadership that will drive our collective vision forward,” Zekulin said in a statement.

Canopy Growth’s biggest investor disappointed with results

Following its blockbuster investment deal into Canopy Growth in November 2017, beverage maker Constellation Brands gained its stake and allowed the marijuana firm to head out and seek a variety of acquisitions with the cash injections it received.

During a quarterly earnings call in June with analysts and investors, Bill Newlands, CEO of Constellation Brands, said his firm was disappointed in the recent quarterly results from Canopy Growth.

As part of its own quarterly results, Constellation Brands indicated that losses tied to the stake in Canopy Growth reached US$106 million on a reported basis, according to a report from the Canadian Press.

“While we remain happy with our investment in the cannabis space and its long-term potential, we were not pleased with Canopy’s recent reported year-end results,” Newlands said.

“However, we continue to aggressively support Canopy on a more focused, long-term strategy to win markets and form factors that matter while paving a clear path to profitability.”

Canopy posted a significant increase in revenues thanks to legalization, but its expansion plans did not help for the bottom line results.

The Canadian producer reported a net loss for Q4 2019 of C$323.3 million for the quarter, resulting in a net loss per share of C$0.98. Over the whole fiscal year, the company posted a net loss of C$685.4 million, indicating a net loss per share of C$2.57.

Canopy also reported an earnings before interest, tax, depreciation and amortization (EBITDA) loss of C$257 million in fiscal 2019, attributed to the investments of the company. The EBITDA loss for the company in fiscal 2018 was C$36.1 million.

Despite an early drop, shares of Canopy Growth quickly saw a marginal rise in Toronto on Wednesday. As of 1:37 p.m. EDT, the firm’s stock was up 1.73 percent to a price of C$53.40.

In New York, the company closed the half trading day—due to the Fourth of July holiday—with a 2.45 percent boost for a price of US$41.06 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less